Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

cis-platinum ototoxicity in children.

R A Weatherly1, J J Owens, F I Catlin

  • 1Department of Otorhinolaryngology and Communicative Sciences, Baylor College of Medicine, Houston, TX 77030.

The Laryngoscope
|September 1, 1991
PubMed
Summary

Cis-platinum chemotherapy can cause hearing loss in children. Younger patients and those with prior radiation exposure are more susceptible. Regular audiologic evaluations are crucial for monitoring treatment effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance of the plant-based repellent TT-4302 against mosquitoes in the laboratory and field and comparative efficacy to 16 mosquito repellents against Aedes aegypti (Diptera: Culicidae).

Journal of medical entomology·2014
Same author

Activity of the plant-based repellent, TT-4302 against the ticks Amblyomma americanum, Dermacentor variabilis, Ixodes scapularis and Rhipicephalus sanguineus (Acari: Ixodidae).

Experimental & applied acarology·2013
Same author

Lung transplantation in a patient with a thrombophilic disorder.

Pediatric transplantation·2008
Same author

Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.

Leukemia·2005
Same author

Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study.

Journal of pediatric hematology/oncology·2002
Same author

Infantile cytomegalovirus-associated autoimmune hemolytic anemia.

Journal of pediatric hematology/oncology·2001

Area of Science:

  • Pediatric Oncology
  • Audiology
  • Ototoxic Drug Monitoring

Background:

  • Cis-platinum is a widely used chemotherapy agent with known ototoxicity.
  • A standardized audiologic evaluation protocol for pediatric patients receiving cis-platinum is lacking.
  • Ototoxicity can lead to significant hearing impairment, impacting quality of life.

Purpose of the Study:

  • To review audiologic evaluations in pediatric patients undergoing cis-platinum therapy.
  • To identify factors influencing cis-platinum-induced hearing loss.
  • To propose guidelines for audiologic monitoring in this population.

Main Methods:

  • Retrospective review of audiograms from 48 pediatric patients.
  • Analysis of auditory brain-stem response (ABR) and pure-tone audiometry results.

Related Experiment Videos

  • Correlation of hearing changes with patient age, cis-platinum dosage, and cranial radiation exposure.

    • Main Results:

    • Younger patients showed increased susceptibility to hearing changes.
    • Hearing loss proportion and severity increased with successive cis-platinum doses.
    • Prior cranial radiation exposure was strongly associated with hearing loss.

    Conclusions:

    • Age, cumulative cis-platinum dose, and cranial radiation are critical factors in ototoxicity.
    • Pure-tone audiometry is a key component in monitoring hearing function.
    • Guidelines for clinical audiometry are proposed for screening pediatric oncology patients.